The first generation PSMA/CD3‐bispecific BiTE antibody AMG212 [MT112 (Micromet, Inc.)/BAY2010112 (Bayer AG)] has been found to potently suppress tumor growth in mouth models as well as in a Phase I study involving 47 mCRPC patients (Hummel et al., 2021). The gene discussed is FOLH1; the disease is neoplasm.